Chen JM, Huang QY, Zhao YX, Chen WH, Lin S, Shi QY
Factors Indicating Need for Dose Escalation Increase doses when minimal subjective improvements after 3-4 weeks at current dose, IGF-1 levels show minimal or no meaningful increase from baseline after an adequate trial period (e.g., 812 weeks), good tolerance without significant side effects suggesting room for higher dosing, and treatment goals require more aggressive approach than current dose provides
Semaglutide, a key ingredient in medications such as Ozempic, Mounjaro, and Wegovy, has drawn significant attention due to emergent research findings related to thyroid tumors, medullary thyroid cancer, and Ozempic side effects
GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes State-of-the-Art. Molecular Metabolism 46 (101102): 101102